Skip to Content

Join the 'Otezla' group to help and get support from people like you.

Otezla News

Early Treatment Equals Better Results for Rheumatoid Arthritis

Posted 25 Apr 2017 by Drugs.com

TUESDAY, April 25, 2017 – Treating rheumatoid arthritis early may make for better outcomes, a new study suggests. Patients who were treated within six months of developing the first signs of the autoimmune disease did better in the long run and were less likely to suffer early death, British researchers found. The findings stem from an analysis of more than 600 patients who were initially ...

Could a Germ Link Gum Disease, Rheumatoid Arthritis?

Posted 15 Dec 2016 by Drugs.com

THURSDAY, Dec. 15, 2016 – A specific germ may help explain the long-noticed connection between gum disease and rheumatoid arthritis, a new study suggests. The discovery might also point to the potential origins of the painful joint illness. "If we're right, this will totally change the view of rheumatoid arthritis and treatment of patients," said study co-author Dr. Felipe Andrade. But, Andrade, ...

Gene Discoveries Could Help Rheumatoid Arthritis Treatment

Posted 28 Apr 2015 by Drugs.com

TUESDAY, April 28, 2015 – Genetic variations may hold clues to rheumatoid arthritis – suggesting not only who will develop the painful condition, but also predicting its severity and even who might die from it, a new study says. "Genetic factors predisposing to disease, to disease severity, and response to treatment will allow tailoring treatment to individual patients' needs," said lead ...

Some Arthritis Meds Cost Seniors Thousands Annually

Posted 21 Apr 2015 by Drugs.com

TUESDAY, April 21, 2015 – Arthritis medications known as biologic disease-modifying drugs can cost Medicare patients more than $2,700 in co-payments a year, a new report finds. Researchers say the tab is an immense burden on patients with disabling conditions such as rheumatoid arthritis, a chronic disorder that affects an estimated 1.3 million Americans. Biologic anti-rheumatic medications – ...

FDA Approves Otezla (apremilast) for Moderate to Severe Plaque Psoriasis

Posted 23 Sep 2014 by Drugs.com

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation today announced that the U.S. Food and Drug Administration (FDA) has approved Otezla (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), for the treatment of patients with moderate to severe plaque psoriasis for whom phototherapy or systemic therapy is appropriate. Otezla is the first and only PDE4 inhibitor ...

Ask a Question

Further Information

Related Condition Support Groups

Psoriatic Arthritis, Plaque Psoriasis

Otezla Patient Information at Drugs.com